56 reports

Epidemiology and quality of life in functional gastrointestinal disorders.

  • Digestive System Disorder
  • Gastrointestinal Drug
  • OTC
  • Italy
  • Forecast

The usage of opioids and their adverse effects in gastrointestinal practice: a review.

  • Gastrointestinal Drug
  • Europe
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Progenics Pharmaceuticals, Inc.

The most frequently reported AEs were within the gastrointestinal system organ class. http:/ / ep##. eventpilot. us/ web/ page. php?

  • Drug Discovery And Development
  • Gastrointestinal Drug
  • United States
  • World
  • Furiex Pharmaceuticals, Inc.

Arms Type Arm I Arm II Active Comparator Active Comparator Pantoprazole magnesium (Tecta, Surmera) is a gastrointestinal, anti ulcer agent.

  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Mechanism of Action Vonoprazan fumarate (Takecab) is a novel anti-secretory drug, acts as gastrointestinal Protective Agent, formulated as tablets for the oral route of administration.

  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Mechanism of Action Lafutidine (Protecadin, Stogar) is an anti-ulcer drug and a gastrointestinal agent.

  • Gastrointestinal Drug
  • World
  • AstraZeneca PLC
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E## Countries (%), 2015* Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trials, E## Countries (%), 2015* Proportion of Irritable Bowel Syndrome to Gastrointestinal Clinical Trial

  • Drug Discovery And Development
  • Gastrointestinal Drug
  • United States
  • World
  • Salix Pharmaceuticals, Ltd.

PROPORTION OF NONEROSIVE REFLUX DISEASE (NERD) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2015* PROPORTION OF NONEROSIVE REFLUX DISEASE (NERD) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2015* PROPORTION OF NONEROSIVE REFLUX DISEASE (NERD) TO

  • Gastrointestinal Drug
  • World
  • ALTANA AG
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited

TABLE ##: MICROCAM NAVI - SMALL BOWEL - PRODUCT DESCRIPTION MICROCAM NAVI - UPPER GASTROINTESTINAL DISORDERS PRODUCT OVERVIEW TABLE ##: MICROCAM NAVI - UPPER GASTROINTESTINAL DISORDERS - PRODUCT STATUS TABLE ##: MICROCAM NAVI - UPPER GASTROINTESTINAL DISORDERS - PRODUCT DE

  • Clinical Trial
  • Gastrointestinal Drug
  • United States
  • Company
  • GlobalData's company

ESOPHAGITIS THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY TRIAL STATUS, 2017* CLINICAL TRIALS BY E## COUNTRIES: PROPORTION OF ESOPHAGITIS TO GASTROINTESTINAL CLINICAL TRIALS AMONG THE E## (BRAZIL, RUSSIA, INDIA, CHINA, MEXICO, TURKEY AND INDONESIA) COUNTRIES, BRAZIL HAVE THE HIGHEST PROPORTI

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • World

IBS is one of the most common gastrointestinal disorders##.

  • Gastrointestinal Drug
  • Opioid
  • Pharmaceutical
  • World
  • Product Initiative

PROPORTION OF ESOPHAGEAL DISEASES TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF ESOPHAGEAL DISEASES TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* IN TOTAL THERE WERE ## CLINICAL TRIALS CONDUCTED ON ESOPHAGEAL DISEASES, AS OF AUGUST 2017

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • World

PROPORTION OF EMESIS (VOMITING) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF EMESIS (VOMITING) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF EMESIS (VOMITING) TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%),

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • Product Initiative

PROPORTION OF DUODENAL ULCER TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* PROPORTION OF DUODENAL ULCER TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* In total there were ## clinical trials conducted on Duodenal Ulcer, as of July 2017 in G## Countries, o

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • Product Initiative

PROPORTION OF CONSTIPATION TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* PROPORTION OF CONSTIPATION TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* PROPORTION OF CONSTIPATION TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* Country N

  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • Braintree Laboratories Inc.

PROPORTION OF DYSPEPSIA TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2017 2017 trials are taken as of July 2017 PROPORTION OF DYSPEPSIA TO

  • Clinical Trial
  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • Yt Blood Group

PROPORTION OF BARRETTS ESOPHAGUS TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF BARRETTS ESOPHAGUS TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* AS OF APRIL 2017, THERE WERE ## CLINICAL TRIALS IN PHASE II, OF WHICH THREE CLINICAL TRIALS WE

  • Gastrointestinal Drug
  • Hospital
  • Therapy
  • World
  • Product Initiative

PROPORTION OF FUNCTIONAL (NON ULCER) DYSPEPSIA TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF FUNCTIONAL (NON ULCER) DYSPEPSIA TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF FUNCTIONAL (NON ULCER) DYSPEPSIA TO

  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • Product Initiative
  • Yt Blood Group

PROPORTION OF FECAL INCONTINENCE TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF FECAL INCONTINENCE TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF FECAL INCONTINENCE TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%

  • Gastrointestinal Drug
  • Therapy
  • World
  • Product Initiative
  • RDD Pharma

PROPORTION OF CORROSIVE ESOPHAGITIS (EROSIVE ESOPHAGITIS) TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* PROPORTION OF CORROSIVE ESOPHAGITIS (EROSIVE ESOPHAGITIS) TO GASTROINTESTINAL CLINICAL TRIALS, G## COUNTRIES (%), 2017* In total there were ## clinical trials condu

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Therapy
  • World
  • Takeda Pharmaceutical Company Limited

PROPORTION OF ACIDITY TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF ACIDITY TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF ACIDITY TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* Source: GlobalData'

  • Gastrointestinal Drug
  • Therapy
  • World
  • Product Initiative
  • Bayer AG

Upper gastrointestinal endoscopy will be performed prior to drug treatment, and at the end of the ##-day study period.

  • Drug Discovery And Development
  • Gastrointestinal Drug
  • World
  • Product Initiative
  • AstraZeneca PLC

Evoke Pharma Inc (Evoke Pharma) is a specialty pharmaceutical company that develops drugs to treat gastrointestinal diseases.

  • Gastrointestinal Drug
  • Healthcare
  • Pharmaceutical
  • United States
  • Evoke Pharma, Inc.

Its products portfolio includes antibiotics, infusions, containing amino acid, vitamin and hepatic protect infusions; gastrointestinal agents, comprising of digestives and antiulcerants.

  • Gastrointestinal Drug
  • South Korea
  • Corporate Finance
  • M&A
  • Biopharmaceuticals Inc.

EA Pharma Co., Ltd., exclusive licensee of elobixibat to treat gastrointestinal (GI) disorders in Japan and other select countries in Asia, conducted the trial.

  • Drug Discovery And Development
  • Gastrointestinal Drug
  • Pharmaceutical
  • World
  • Product Initiative

PROPORTION OF ACID INDIGESTION / HEARTBURN/ PYROSIS TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF ACID INDIGESTION / HEARTBURN/ PYROSIS TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF ACID INDIGESTION /

  • Digestive System Disorder
  • Gastrointestinal Drug
  • OTC
  • World
  • Product Initiative

PROPORTION OF INFECTIOUS DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF INFECTIOUS DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES (%), 2017* PROPORTION OF INFECTIOUS DIARRHEA TO GASTROINTESTINAL CLINICAL TRIALS, E## COUNTRIES

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Pathology
  • World
  • Product Initiative

Seeto has published several publications in peer-reviewed journals, including publications focused on his work in gastrointestinal research.

  • Gastrointestinal Drug
  • United States
  • Company
  • Company Operations
  • Ardelyx, Inc.

IBS is one of the most common gastrointestinal disorders.

  • Clinical Trial
  • Digestive System Disorder
  • Gastrointestinal Drug
  • World
  • GlaxoSmithKline plc

Proportion of Zollinger-Ellison Syndrome (Gastrinoma) to Gastrointestinal Clinical Trials, E## Countries (%), 2016* Proportion of Zollinger-Ellison Syndrome (Gastrinoma) to Gastrointestinal Clinical Trials, E## Countries (%), 2016* Proportion of Zollinger-Ellison Syndrome (Gastrinoma

  • Digestive System Disorder
  • Gastrointestinal Drug
  • Hospital
  • World
  • Product Initiative